Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.61 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | LAP3 | P28838 | 4/20 | 0.39 |
| ▸ | ANPEP | P15144 | 2/20 | 0.39 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.39 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6444909 | 0.82 | AOC3 (0.54) | CSNK1EAOC3SPPL2AEPHX1TRPA1 | |
| SCHEMBL6447559 | 0.80 | CSNK1E (0.49) | CSNK1EAOC3SPPL2AEPHX1LAP3 | |
| SCHEMBL27648870 | 0.79 | CSNK1E (0.88) | CSNK1ERENEPHX1TRPA1LAP3 | |
| SCHEMBL4516038 | 0.79 | CSNK1E (0.88) | CSNK1ERENEPHX1TRPA1LAP3 | |
| SCHEMBL4508560 | 0.79 | CSNK1E (0.88) | CSNK1ERENEPHX1TRPA1LAP3 | |
| SCHEMBL496237 | 0.77 | CSNK1E (0.55) | CSNK1ESPPL2AEPHX1TRPA1LAP3 | |
| SCHEMBL10065927 | 0.76 | CSNK1E (0.59) | CSNK1E | |
| SCHEMBL13679081 | 0.76 | CSNK1E (0.59) | CSNK1E | |
| Hydrochloric Acid SCHEMBL496260 | 0.75 | CSNK1E (0.54) | CSNK1ESPPL2AEPHX1TRPA1LAP3 | |
| Hydrochloric Acid SCHEMBL15062952 | 0.75 | CSNK1E (0.54) | CSNK1ESPPL2AEPHX1TRPA1LAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | claimed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| US-5670497-A | RETROVIRAL PROTEASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | disclosed |
| EP-0708760-A1 | CYCLIC HYDRAZINE COMPOUNDS | Novartis AG (CH) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995002582-A1 | CYCLIC HYDRAZINE COMPOUNDS | CIBA-GEIGY AG (CH) | 1995-01-26 | — | — | WO | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | CSNK1E 954/4885AOC3 1192/4885SPPL2A 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.